Quilter Plc Increases Stake in Eli Lilly and Company $LLY

Quilter Plc increased its holdings in Eli Lilly and Company (NYSE:LLY) by 18.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,268 shares of the company’s stock after acquiring an additional 2,835 shares during the quarter. Quilter Plc’s holdings in Eli Lilly and Company were worth $14,240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the business. Clal Insurance Enterprises Holdings Ltd raised its stake in Eli Lilly and Company by 0.6% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 86,570 shares of the company’s stock valued at $67,484,000 after buying an additional 515 shares during the last quarter. Haverford Financial Services Inc. boosted its position in Eli Lilly and Company by 120.0% in the second quarter. Haverford Financial Services Inc. now owns 8,126 shares of the company’s stock worth $6,334,000 after purchasing an additional 4,433 shares during the last quarter. Empirical Finance LLC increased its holdings in Eli Lilly and Company by 0.7% during the second quarter. Empirical Finance LLC now owns 27,659 shares of the company’s stock valued at $21,561,000 after buying an additional 182 shares during the last quarter. TD Waterhouse Canada Inc. grew its holdings in Eli Lilly and Company by 4.8% during the second quarter. TD Waterhouse Canada Inc. now owns 84,737 shares of the company’s stock valued at $65,772,000 after purchasing an additional 3,899 shares during the period. Finally, TRUE Private Wealth Advisors lifted its stake in shares of Eli Lilly and Company by 7.2% during the 2nd quarter. TRUE Private Wealth Advisors now owns 7,366 shares of the company’s stock valued at $5,742,000 after buying an additional 497 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.8%

Shares of LLY opened at $1,048.90 on Thursday. The stock’s 50-day moving average price is $844.09 and its 200-day moving average price is $784.22. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $991.61 billion, a price-to-earnings ratio of 68.56, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,055.59.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on LLY shares. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. UBS Group increased their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Daiwa Capital Markets raised their target price on shares of Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,027.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.